Author
Listed:
- Ghayas C. Issa
(The University of Texas MD Anderson Cancer Center)
- Ibrahim Aldoss
(City of Hope)
- John DiPersio
(Washington University School of Medicine in St. Louis)
- Branko Cuglievan
(The University of Texas MD Anderson Cancer Center)
- Richard Stone
(Dana-Farber Cancer Institute)
- Martha Arellano
(Emory University School of Medicine)
- Michael J. Thirman
(University of Chicago)
- Manish R. Patel
(Florida Cancer Specialists/Sarah Cannon Research Institute)
- David S. Dickens
(University of Iowa)
- Shalini Shenoy
(Washington University School of Medicine in St. Louis)
- Neerav Shukla
(Memorial Sloan Kettering Cancer Center)
- Hagop Kantarjian
(The University of Texas MD Anderson Cancer Center)
- Scott A. Armstrong
(Dana-Farber Cancer Institute)
- Florian Perner
(Dana-Farber Cancer Institute
Greifswald University Medical Center)
- Jennifer A. Perry
(Dana-Farber Cancer Institute)
- Galit Rosen
(Syndax Pharmaceuticals)
- Rebecca G. Bagley
(Syndax Pharmaceuticals)
- Michael L. Meyers
(Syndax Pharmaceuticals)
- Peter Ordentlich
(Syndax Pharmaceuticals)
- Yu Gu
(Syndax Pharmaceuticals)
- Vinit Kumar
(Syndax Pharmaceuticals)
- Steven Smith
(Syndax Pharmaceuticals)
- Gerard M. McGeehan
(Syndax Pharmaceuticals)
- Eytan M. Stein
(Memorial Sloan Kettering Cancer Center)
Abstract
Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function1–3. The interaction of menin with lysine methyltransferase 2A (KMT2A), an epigenetic regulator, is a dependence in acute leukaemia caused by either rearrangement of KMT2A or mutation of the nucleophosmin 1 gene (NPM1)4–6. KMT2A rearrangements occur in up to 10% of acute leukaemias and have an adverse prognosis, whereas NPM1 mutations occur in up to 30%, forming the most common genetic alteration in acute myeloid leukaemia7,8. Here, we describe the results of the first-in-human phase 1 clinical trial investigating revumenib (SNDX-5613), a potent and selective oral inhibitor of the menin–KMT2A interaction, in patients with relapsed or refractory acute leukaemia (ClinicalTrials.gov, NCT04065399). We show that therapy with revumenib was associated with a low frequency of grade 3 or higher treatment-related adverse events and a 30% rate of complete remission or complete remission with partial haematologic recovery (CR/CRh) in the efficacy analysis population. Asymptomatic prolongation of the QT interval on electrocardiography was identified as the only dose-limiting toxicity. Remissions occurred in leukaemias refractory to multiple previous lines of therapy. We demonstrate clearance of residual disease using sensitive clinical assays and identify hallmarks of differentiation into normal haematopoietic cells, including differentiation syndrome. These data establish menin inhibition as a therapeutic strategy for susceptible acute leukaemia subtypes.
Suggested Citation
Ghayas C. Issa & Ibrahim Aldoss & John DiPersio & Branko Cuglievan & Richard Stone & Martha Arellano & Michael J. Thirman & Manish R. Patel & David S. Dickens & Shalini Shenoy & Neerav Shukla & Hagop , 2023.
"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia,"
Nature, Nature, vol. 615(7954), pages 920-924, March.
Handle:
RePEc:nat:nature:v:615:y:2023:i:7954:d:10.1038_s41586-023-05812-3
DOI: 10.1038/s41586-023-05812-3
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:615:y:2023:i:7954:d:10.1038_s41586-023-05812-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.